Advertisement

Drugs

pp 1–1 | Cite as

Correction to: Triamcinolone Aceonide Extended-Release: A Review in Osteoarthritis Pain of the Knee

  • Julia PaikEmail author
  • Sean T. Duggan
  • Susan J. Keam
Correction
  • 150 Downloads

1 Correction to: Drugs (2019) 79:455–462  https://doi.org/10.1007/s40265-019-01083-3

An Online First version of this article was made available online at https://rd.springer.com/article/10.1007/s40265-019-01083-3 on the 8th of March 2019. Two errors were identified in the article; please note the following:
  1. 1.

    Page 456, Column 2, Paragraph 1, Lines 2–7: The following sentence, which previously read:

    “Both triamcinolone acetonide ER 40 mg and triamcinolone acetonide CS 40 mg were associated with significant reductions in 24 h weighted mean serum cortisol (maximum reduction within 24 h of administration of 42.7 vs. 59.0%) and 24 h urinary cortisol excretion (43.8 vs. 58.5%) from baseline.”

    Should read:

    “Both triamcinolone acetonide ER 32 mg and triamcinolone acetonide CS 40 mg were associated with significant reductions in 24 h weighted mean serum cortisol (maximum reduction within 24 h of administration of 42.7 vs. 59.0%) and 24 h urinary cortisol excretion (43.8 vs. 58.5%) from baseline.”

     
  2. 2.

    Page 457, Column 1, Paragraph 1, Lines 12–14: The following sentence, which previously read:

    “By contrast, the mean concentration of triamcinolone acetonide ER 6 weeks after treatment with 1 mL triamcinolone acetonide CS 40 mg was 0.0077 ng/mL [24].”

    Should read:

    “By contrast, the mean concentration of triamcinolone acetonide 6 weeks after treatment with 1 mL triamcinolone acetonide CS 40 mg was 0.0077 ng/mL [24].”

     

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations